MEDICINAL PROVISION FOR PATIENTS WITH VIRAL HEPATITIS IN THE KYRGYZ REPUBLIC AT THE PRESENT STAGE
In 2019, 10,580 cases of newly diagnosed viral hepatitis were registered in the Kyrgyz Republic against 10,373 cases in 2018, i.e. the incidence of chronic viral hepatitis remains at the same level. Treatment of chronic viral hepatitis remains costly, placing a great burden on both the individual patient and the country's health system as a whole. The article presents the results of studying the availability and analysis of the comparative effectiveness of drugs used in the treatment of chronic viral hepatitis. As a result of the analysis, it was established that currently 35 names of antiviral drugs of this group are allowed for medical use in the Kyrgyz Republic, which shows the availability of physical availability of drugs for the treatment of chronic viral hepatitis. At the same time, drugs in this group remain economically inaccessible for the majority of the population of Kyrgyzstan, and the state currently does not provide programs to reduce the cost of treating the disease.